Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2006
09/05/2006US7101893 Treating hyperproliferative disorders; N-(4-trifluoromethoxyphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide
09/05/2006US7101892 2-(4-benzenesulfonyl-4-methyl-pentyl)-5-phenyl-2-aza-bicyclo[2.2.1]heptane; useful for treating sleep disorder, depression, anxiety
09/05/2006US7101891 Compounds and pharmaceutical compositions for inhibiting MRP1
09/05/2006US7101890 Benzazepine derivatives, drugs containing these and use of the same for producing drugs
09/05/2006US7101889 Lipase inhibiting composition
09/05/2006US7101888 Oral liquid tolterodine composition
09/05/2006US7101887 Treating neuropsycological diseases; schizophrenia, psychotic depression and mania
09/05/2006US7101886 such as N-{2-[2-(4-1,2-Benzisothiazol-3-yl-piperazin-1-yl)-ethyl]-phenyl}-2-(2,5-dimethoxy-phenyl)-acetamide; antagonists of dopamine D2 receptors and of serotonin 2A (5HT2a) receptors; for treatment of depression and dementia/schizophrenia
09/05/2006US7101885 1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; antagonists of the serotonin 5HT1B receptor; treating depression
09/05/2006US7101884 Tyrosine kinase inhibitors
09/05/2006US7101883 Antiinflammatory agents, antiischemic agents, malaria, Crohn's disease, skin disorders
09/05/2006US7101882 Morpholin-acetamide derivatives for the treatment of inflammatory diseases
09/05/2006US7101881 N-(4-Chlorophenylacetyl)-8-(4-methylpiperazinyl)-tetrahydroisoquinoline; treating anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder, phobias
09/05/2006US7101880 Peptidic compounds as cysteine protease inhibitors
09/05/2006US7101879 Decreasing the membrane depolarization by antagonizing beta amyloid peptide aggregation
09/05/2006US7101878 Non-peptide GNRH agents, methods and intermediates for their preparation
09/05/2006US7101877 Trans-[2-(4-Morpholinyl)-1-(2-Naphthenethoxy)]Cyclohexane Monohydrochloride; selectively inhibiting cardiac early repolarising currents and cardiac sodium currents
09/05/2006US7101876 Substituted benzoxazines as integrin antagonists
09/05/2006US7101875 E.g., 4-(2-(1-Benzhydryl-2-(2-((benzylsulfonyl)amino)ethyl)-5-chloro-1H-indol-3 -yl)ethoxy)benzoic acid; inhibitors of phospholipase enzymes, esp. phospholipase A2; antiarthritic and -inflammatory agents; analgesics; rheumatoid diseases
09/05/2006US7101874 1) N-[[(5S)-3-[4-(2,3-dihydro-1,1-dioxido-4H-1,4-thiazin-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; potent activities against Gram-positive and Gram-negative bacteria
09/05/2006US7101873 Pyrimidinedione derivatives
09/05/2006US7101872 Farnesyl dibenzodiazepinone, and processes for its production
09/05/2006US7101871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
09/05/2006US7101870 2R,3S) N1-[6,7-dihydro-5-(3-phenoxybenzyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide; treating Alzheimer's disease and Down's Syndrome by inhibiting production of A beta -peptide
09/05/2006US7101869 2,4-diaminopyrimidine compounds useful as immunosuppressants
09/05/2006US7101868 A 2-(((4-fluorophenyl)methyl)amino)-3-pyridinecarboxamide derivatives for treating cancer, angiogenesis, tumor
09/05/2006US7101867 Benzofuran derivatives, their production and use
09/05/2006US7101866 6,9-Difluoro-17 alpha -((2-furanylcarbonyl)oxy)-11 beta -hydroxy-16 alpha -methyl-3-oxo-androsta-1,4-diene-17 beta -carbothioic acid S-fluoromethyl ester; antiinflammatory agents for the treatment of allergic conditions
09/05/2006US7101865 24-sulfoximine vitamin D3 compounds
09/05/2006US7101864 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells
09/05/2006US7101863 For skin, muscle, ocular or gastric mucosal healing
09/05/2006US7101862 Hemostatic compositions and methods for controlling bleeding
09/05/2006US7101861 For therapy and prophylaxis of host infected with flavivirus or pestivirus
09/05/2006US7101860 Composition and method for inhibiting platelet aggregation
09/05/2006US7101859 Use of lipid conjugates in the treatment of diseases
09/05/2006US7101858 Methylation in presence of base and a solvent; reacting with acid
09/05/2006US7101857 Crosslinkable biological material and medical uses
09/05/2006US7101856 Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
09/05/2006US7101853 Provided amylin agonist is not calcitonin; also amylin used in combination with an nonsteroidal antiinflammatory agent to relieve pain, thereby achieving a synergistic effect
09/05/2006US7101846 Methods and compositions for optimization of oxygen transport by cell-free systems
09/05/2006US7101842 Such as transferrin-doxorubicin conjugate linked by gluteraldehyde; inexpensive, effective
09/05/2006US7101711 Activating a T gamma 9 delta 2 lymphocyte at a minimum activation concentration of below 100 nM, in vitro by contacting with a 3,4-epoxy-3-methyl-1-butyl diphosphate substituted with a biomolecule
09/05/2006US7101705 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
09/05/2006US7101702 Fermentative preparation process for and crystal forms of cytostatics
09/05/2006US7101693 Plasticized hydrophilic glasses for improved stabilization of biological agents
09/05/2006US7101689 Interleukin-18 binding proteins, their preparation and use
09/05/2006US7101576 Nanoparticles of megestrol, megestrol acetate, or a salt and a stabilizer is assocated with the surface of the nanoparticle
09/05/2006US7101574 Pharmaceutical composition containing fenofibrate and the preparation method
09/05/2006US7101572 Taste masked aqueous liquid pharmaceutical composition
09/05/2006US7101569 Dispersing an immediate release levothyroxine pharmaceutical tablet in an aqueous medium for less than ten minutes
09/05/2006US7101568 Biodegradation organophosphorus polymer; administering to tumor in situ
09/05/2006US7101564 Plastically deformable implant
09/05/2006US7101562 Conjugate vaccines for the prevention of dental caries
09/05/2006US7101559 Immunomodulatory protein and useful embodiments thereof
09/05/2006US7101553 Administering prebiotic such as fructo-oligosaccharide; measles prevention; vaccines; nutrients
09/05/2006US7101551 Substance which inhibits binding between E2/NS1 protein of hepatitis C virus and cell infectious with hepatitis C virus, a cell expressing CD81, or CD81
09/05/2006US7101548 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
09/05/2006US7101543 Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
09/05/2006US7101394 biologically active material and magnetic particles on the surface, a second polymeric layer free of the biologically active material; when activated magnetic particles move out of the second coating layer and create channels through which the biologically active material can be released
09/05/2006US7101386 Patient temperature regulation method and apparatus
09/05/2006US7101375 Spine distraction implant
09/05/2006CA2412885C Porous celecoxib matrices and methods of manufacture thereof
09/05/2006CA2393640C Pyrrolo[2,3-d]pyrimidine compounds
09/05/2006CA2261022C System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
09/05/2006CA2259353C Plaster for the transdermal application of pergolide
09/05/2006CA2246668C Low ph germicidal iodine compositions having enhanced stability
09/05/2006CA2214027C Multiple unit effervescent dosage forms comprising proton pump inhibitor
09/05/2006CA2206567C Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
09/05/2006CA2187484C Process for the preparation of enantiomerically pure imidazolyl compounds
09/02/2006CA2513350A1 Treatment for multiple sclerosis
09/02/2006CA2498639A1 Niacin used as oral supplementation for the treatment and prevention of sexual dysfunction in human males and females
08/2006
08/31/2006WO2006091988A1 Composition for treating mental health disorders
08/31/2006WO2006091974A1 Tadalafil having a large particle size and a process for preparation thereof
08/31/2006WO2006091972A2 Dimeric iap inhibitors
08/31/2006WO2006091963A1 Tetrahydroindolone and tetrahydroindazolone derivatives
08/31/2006WO2006091941A2 Compositions and methods for treating and preventing cardiomyopathy and heart disease
08/31/2006WO2006091922A1 Dronabinol compositions and methods of using same
08/31/2006WO2006091905A1 Bicyclo (3.1.0) hexane derivatives as antiviral compounds
08/31/2006WO2006091903A1 Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
08/31/2006WO2006091898A2 Pyrazolyl substituted xanthines
08/31/2006WO2006091897A2 Derivatives of 8-substituted xanthines
08/31/2006WO2006091896A2 Pyridyl substituted xanthines
08/31/2006WO2006091895A2 Method for the treatment of retinopathy of prematurity and related retinopathic diseases
08/31/2006WO2006091894A2 New polymeric materials and methods
08/31/2006WO2006091887A2 Methods of modulating tnf using bupropion
08/31/2006WO2006091885A2 A registry method and control system for dea schedule ii-v medicines
08/31/2006WO2006091858A1 Benzisothiazoles useful for treating or preventing hcv infection
08/31/2006WO2006091841A2 Compositions and their uses directed to il-4r alpha
08/31/2006WO2006091837A2 Small molecule inhibitors of stat3 and the uses thereof
08/31/2006WO2006091801A2 Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors
08/31/2006WO2006091800A2 Novel pyridine derivatives as potassium ion channel openers
08/31/2006WO2006091798A2 Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
08/31/2006WO2006091769A1 Novel quinoline derivatives as potassium ion channel openers
08/31/2006WO2006091761A1 Methods for treatment of retinal degenerative disease
08/31/2006WO2006091737A1 Modulators of gsk-3 activity
08/31/2006WO2006091732A1 Processes for preparing sertraline
08/31/2006WO2006091725A1 Treatment of anhedonia
08/31/2006WO2006091722A2 Alkyl-glycoside enhanced vaccination
08/31/2006WO2006091720A2 Compositions and methods for targeted delivery of immune response modifiers
08/31/2006WO2006091716A2 Nitric oxide enhancing diuretic compounds, compositions and methods of use